<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574834</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00044872-Ramipril</org_study_id>
    <nct_id>NCT00574834</nct_id>
  </id_info>
  <brief_title>Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes</brief_title>
  <official_title>Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King Pharmaceuticals is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be focused on determining the integrated in-vivo mechanisms responsible for
      Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels)
      glycemia in patients with impaired glucose tolerance.

      Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal
      glycemia in patients with impaired glucose tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have demonstrated that therapeutic agents used to reduce glucose levels
      and/or weight can delay the onset of type 2 diabetes. Intriguingly, angiotensin converting
      enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) also result in reduction in
      the onset of type 2 DM. The most striking effect was found with Ramipril in the HOPE study.
      The onset of new type 2 DM was reduced by 34% (p&lt;0.001) as compared to placebo. Furthermore,
      the results of the DREAM trial demonstrate that Ramipril at a dose of 15 mg can significantly
      reverse impaired glucose tolerance. However, the mechanisms underlying Ramipril effects to
      delay type 2 diabetes are not known.

      The proposal will be focused on determining the integrated in-vivo mechanisms responsible for
      Ramipril's effects on delaying type 2 DM and restoring normal glycemia in patients with
      impaired glucose tolerance.

      The specific aims of the project are:

        -  to determine the effect of Ramipril on insulin resistance at the level of the liver and
           peripheral tissues,

        -  to determine the effect of Ramipril on endothelial function,

        -  to determine the effects of Ramipril on insulin secretion, and

        -  to determine the effects of Ramipril on substrate flux, lipolysis and inflammatory
           cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Insulin Sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>Measures of change in endogenous glucose production from baseline to final 30 minutes of clamp studies after 6 months of treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to 6 months treatment of Ramipril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PAtients randomized to 6 months treatment of HCTZ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril+HCTZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to 6 months treatment of Ramipril+HCTZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Ramipril 20 mg once daily for 6 months</description>
    <arm_group_label>Ramipril</arm_group_label>
    <other_name>Altace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ-hydrochlorothiazide</intervention_name>
    <description>HCTZ 25 mg once daily for 6 months</description>
    <arm_group_label>HCTZ</arm_group_label>
    <other_name>Brand Names: HydroDIURIL, Microzide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril+HCTZ</intervention_name>
    <description>Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months</description>
    <arm_group_label>Ramipril+HCTZ</arm_group_label>
    <other_name>Altace and HydroDIURIL, Microzide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  48 (24 male / 24 female) with impaired glucose tolerance.

          -  Impaired blood glucose values as outlined by the American Diabetes Association
             guideline. Fasting plasma glucose between 100 and 126 mg/dl or 2 hour post prandial
             glucose between 140 and 200 mg/dl

          -  BMI &gt; 25 kgM2

          -  Age: 20-65 years

          -  Treated or Untreated hypertension defined as measurement of seated BP at screening
             visit of systolic BP 120 to 150 and/ or diastolic BP 80 to 100.

        Exclusion:

          -  Patients receiving agents that can increase or lower blood glucose, i.e., metformin,
             thiazolidinediones, sulfonylureas, glitinides, acarbose, GLP-1 receptor agonists

          -  Untreated or treated while seated Systolic Blood pressure &gt;150and/or Diastolic Blood
             pressure &gt;100

          -  Taking hypertensive medications of HCTZ or ACE/ARB

          -  Allergy to HCTZ, heparin, nitroglycerin or lidocaine

          -  History of allergy or unacceptable side effects from ACE inhibitors

          -  Pregnancy or intent to become pregnant during the study

          -  Smoking

          -  Subject unable to give voluntary informed consent

        Physical Exam Exclusion Criteria

          -  Clinically significant Cardiac Abnormalities (e.g. Heart Failure, Arrhythmia) from
             history or ECG in subjects &gt; 40 years old

          -  Pneumonia

          -  Hepatic Failure/Jaundice

          -  Renal Failure

          -  Acute Cerebrovascular/ Neurological deficit

          -  Fever greater than 38.0 C

        Screening Laboratory Tests Exclusion Criteria according to protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N. Davis, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <results_first_submitted>December 10, 2015</results_first_submitted>
  <results_first_submitted_qc>December 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2016</results_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Individuals with pre-diabetes (metabolic syndrome) are recruited for a 6 month study intervention.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ramipril</title>
          <description>Patients randomized to 6 months treatment of Ramipril.
Ramipril: Ramipril 20 mg once daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>HCTZ</title>
          <description>Patients randomized to 6 months treatment of HCTZ.
HCTZ-hydrochlorothiazide: HCTZ 25 mg once daily for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Ramipril+HCTZ</title>
          <description>Patients randomized to 6 months treatment of Ramipril+HCTZ.
Ramipril+HCTZ: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ramipril</title>
          <description>Patients randomized to 6 months treatment of Ramipril.
Ramipril: Ramipril 20 mg once daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>HCTZ</title>
          <description>Patients randomized to 6 months treatment of HCTZ.
HCTZ-hydrochlorothiazide: HCTZ 25 mg once daily for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Ramipril+HCTZ</title>
          <description>Patients randomized to 6 months treatment of Ramipril+HCTZ.
Ramipril+HCTZ: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="8.5"/>
                    <measurement group_id="B2" value="46" spread="9"/>
                    <measurement group_id="B3" value="41" spread="13"/>
                    <measurement group_id="B4" value="46" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Insulin Sensitivity</title>
        <description>Measures of change in endogenous glucose production from baseline to final 30 minutes of clamp studies after 6 months of treatment.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ramipril</title>
            <description>Patients randomized to 6 months treatment of Ramipril.
Ramipril: Ramipril 20 mg once daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>HCTZ</title>
            <description>Patients randomized to 6 months treatment of HCTZ.
HCTZ-hydrochlorothiazide: HCTZ 25 mg once daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Ramipril+HCTZ</title>
            <description>Patients randomized to 6 months treatment of Ramipril+HCTZ.
Ramipril+HCTZ: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Insulin Sensitivity</title>
          <description>Measures of change in endogenous glucose production from baseline to final 30 minutes of clamp studies after 6 months of treatment.</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.36"/>
                    <measurement group_id="O2" value="1.5" spread="0.23"/>
                    <measurement group_id="O3" value="1.2" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ramipril</title>
          <description>Patients randomized to 6 months treatment of Ramipril.
Ramipril: Ramipril 20 mg once daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>HCTZ</title>
          <description>Patients randomized to 6 months treatment of HCTZ.
HCTZ-hydrochlorothiazide: HCTZ 25 mg once daily for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Ramipril+HCTZ</title>
          <description>Patients randomized to 6 months treatment of Ramipril+HCTZ.
Ramipril+HCTZ: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results of this trial were too preliminary to report. Trial was ended due to lack of funding to complete. No conclusions could be drawn from existing data.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed. No conclusions drawn.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stephen N. Davis, MBBS- Principal Investigator</name_or_title>
      <organization>University of Maryland Baltimore</organization>
      <phone>410-328-2488</phone>
      <email>sdavis@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

